127 related articles for article (PubMed ID: 3416297)
1. Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.
Friedman HS; Skapek SX; Colvin OM; Elion GB; Blum MR; Savina PM; Hilton J; Schold SC; Kurtzberg J; Bigner DD
Cancer Res; 1988 Oct; 48(19):5397-402. PubMed ID: 3416297
[TBL] [Abstract][Full Text] [Related]
2. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.
Friedman HS; Colvin OM; Skapek SX; Ludeman SM; Elion GB; Schold SC; Jacobsen PF; Muhlbaier LH; Bigner DD
Cancer Res; 1988 Aug; 48(15):4189-95. PubMed ID: 3390813
[TBL] [Abstract][Full Text] [Related]
3. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
Pu Q; Bianchi P; Bezwoda WR
Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide resistance in medulloblastoma.
Friedman HS; Colvin OM; Kaufmann SH; Ludeman SM; Bullock N; Bigner DD; Griffith OW
Cancer Res; 1992 Oct; 52(19):5373-8. PubMed ID: 1356617
[TBL] [Abstract][Full Text] [Related]
5. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.
Laskowitz DT; Elion GB; Dewhirst MW; Griffith OW; Savina PM; Blum MR; Prescott DM; Bigner DD; Friedman HS
Radiat Res; 1992 Feb; 129(2):218-23. PubMed ID: 1734453
[TBL] [Abstract][Full Text] [Related]
8. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
[TBL] [Abstract][Full Text] [Related]
9. The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma.
Groothuis DR; Lippitz BE; Fekete I; Schlageter KE; Molnar P; Colvin OM; Roe CR; Bigner DD; Friedman HS
Cancer Res; 1992 Oct; 52(20):5590-6. PubMed ID: 1394182
[TBL] [Abstract][Full Text] [Related]
10. Experimental chemotherapy of human medulloblastoma with classical alkylators.
Friedman HS; Colvin OM; Ludeman SM; Schold SC; Boyd VL; Mulhbaier LH; Bigner DD
Cancer Res; 1986 Jun; 46(6):2827-33. PubMed ID: 3698009
[TBL] [Abstract][Full Text] [Related]
11. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Danks MK; Pawlik CA; Whipple DO; Wolverton JS
Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.
Lilley ER; Elion GB; Dewhirst MW; Schold SC; Blum MR; Savina PM; Laskowitz DT; Bigner DD; Friedman HS
Cancer Res; 1991 Aug; 51(15):3906-9. PubMed ID: 1855207
[TBL] [Abstract][Full Text] [Related]
14. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
15. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
[TBL] [Abstract][Full Text] [Related]
16. Differential specificity of monochlorobimane for isozymes of human and rodent glutathione S-transferases.
Cook JA; Iype SN; Mitchell JB
Cancer Res; 1991 Mar; 51(6):1606-12. PubMed ID: 1998951
[TBL] [Abstract][Full Text] [Related]
17. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
[TBL] [Abstract][Full Text] [Related]
18. In vitro versus in vivo correlations of chemosensitivity of human medulloblastoma.
Friedman HS; Schold SC; Muhlbaier LH; Bjornsson TD; Bigner DD
Cancer Res; 1984 Nov; 44(11):5145-9. PubMed ID: 6488174
[TBL] [Abstract][Full Text] [Related]
19. Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
Moscow JA; Swanson CA; Cowan KH
Br J Cancer; 1993 Oct; 68(4):732-7. PubMed ID: 8398701
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.
Lilley ER; Rosenberg MC; Elion GB; Colvin OM; Bigner DD; Friedman HS
Cancer Res; 1990 Jan; 50(2):284-7. PubMed ID: 2295068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
